The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis
Abstract
Objective: B cell depletion with rituximab has allowed remissions in relapsing or refractory antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in small studies. The aim of this study was to determine the efficacy and safety of rituximab for ANCA‐associated vasculitis in a larger multicenter cohort. This permitted comparison of rituximab dosing regimens, the value of continuing immunosuppression, and investigation of ANCA and B cell levels as re‐treatment biomarkers. Methods: Retrospective, standardized data collection from 65 sequential patients receiving rituximab for refractory ANCA‐associated vasculitis at 4 centers in the UK was used. Results: All patients achieved B cell depletion. Complete remission occurred in 49 of the 65 patients (75%), partial remission in 15 (23%), and no response in 1 (2%). The prednisolone dosage was reduced from 12.5 mg/day (median) to 9.0 mg/day at 6 months (P = 0.0006). Immunosuppressive therapy was withdrawn in 37 of 60 patients (62%). Twenty‐eight of 49 patients who achieved full remission (57%) experienced relapse (median 11.5 months). B cell return preceded relapse in 14 of 27 patients (52%). Although ANCA levels fell after rituximab therapy, relapse was not associated with ANCA positivity or a rise in ANCA levels. Neither the initial rituximab regimen (4 infusions of 375 mg/m 2 each given 1 week apart or 2 infusions of 1 gm each given 2 weeks apart) nor withdrawal of immunosuppressive therapy (37 of 60 patients [62%]) influenced the timing of relapse. Thirty‐eight patients received ≥2 courses of rituximab, and complete remission was induced or maintained in 32 of them (84%). IgM levels fell, although IgG levels remained stable. Forty‐six serious adverse events occurred, including 2 episodes of late‐onset neutropenia, which were attributed to rituximab. Conclusion: Rituximab was effective remission induction therapy for refractory ANCA‐associated vasculitis in this study. There was no difference in efficacy between the 2 main treatment regimens. Continuing immunosuppression did not reduce relapses. Relapses occurred, but re‐treatment was effective and safe. There was no clear influence of rituximab on the frequency of serious adverse events. ANCA and B cell levels lacked sufficient sensitivity to guide the timing of re‐treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationLooney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Hellmich, B., Flossmann, O., Gross, W. L., Bacon, P., Willem Cohen-Tervaert, J., Guillevin, L., Jayne, D., Mahr, A., Merkel, P. A., Raspe, H., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062711 · Cited by 633
Self-citationMAINTENANCE OF SERUM ANTIBODY LEVELS
Manz, R. A., Hauser, A. E., Hiepe, F., & Radbruch, A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115723 · Cited by 539
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
Booth, A. D., Almond, M. K., Burns, A., Ellis, P., Gaskin, G., Neild, G. H., Plaisance, M., Pusey, C. D., & Jayne, D. R. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00025-8 · Cited by 504
Self-citationKeogh, K. A., Wylam, M. E., Stone, J. H., & Specks, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20718 · Cited by 450
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Smith, K. G. C., Jones, R. B., Burns, S. M., & Jayne, D. R. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22046 · Cited by 400
Self-citationRituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial
Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R., & Specks, U. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1144oc · Cited by 399
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R., & Isenberg, D. A. (2005) · Rheumatology · doi:10.1093/rheumatology/kei080 · Cited by 364
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Anolik, J. H., Barnard, J., Owen, T., Zheng, B., Kemshetti, S., Looney, R. J., & Sanz, I. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22810 · Cited by 333
ERIKSSON, P. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01494.x · Cited by 232
Stasi, R., Stipa, E., Del Poeta, G., Amadori, S., Newland, A. C., & Provan, D. (2006) · Rheumatology · doi:10.1093/rheumatology/kel098 · Cited by 219
Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S., Tsai, D., Pullman-Mooar, S., Barnack, F., Striebich, C., Looney, R. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083162 · Cited by 209
Ng, C. M., Bruno, R., Combs, D., & Davies, B. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005277075 · Cited by 203
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
Vos, K., Thurlings, R. M., Wijbrandts, C. A., van Schaardenburg, D., Gerlag, D. M., & Tak, P. P. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22400 · Cited by 194
Walsh, M., Chaudhry, A., & Jayne, D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081661 · Cited by 178
Self-citationImmunohistochemical analysis as a means to predict responsiveness to rituximab treatment
Teng, Y. K. O., Levarht, E. W. N., Hashemi, M., Bajema, I. M., Toes, R. E. M., Huizinga, T. W. J., & van Laar, J. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22967 · Cited by 171
Pharmacodynamics of Rituximab in Kidney Allotransplantation
Genberg, H., Hansson, A., Wernerson, A., Wennberg, L., & Tydén, G. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01497.x · Cited by 170
Development and validation of a disease extent index for Wegener's granulomatosis.
de Groot, K., Gross, W. L., Herlyn, K., & Reinhold‐Keller, E. (2001) · PubMed · Cited by 166
Mycophenolate Mofetil in Anti-Neutrophil Cytoplasm Antibodies-Associated Systemic Vasculitis
Koukoulaki, M., & Jayne, D. R. W. (2005) · Nephron Clinical Practice · doi:10.1159/000089667 · Cited by 97
Self-citationEffective therapeutic use of rituximab in refractory Wegener's granulomatosis
Ferraro, A. J., Day, C., Drayson, M. T., & Savage, C. O. S. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh599 · Cited by 96
Self-citationMease, P. J., Revicki, D. A., Szechiński, J., Greenwald, M., Kivitz, A., Barile-Fabris, L. A., Kalsi, J., Eames, J. R., & Leirisalo‐Repo, M. (2008) · PubMed · Cited by 93
Infectious complications of monoclonal antibodies used in cancer therapy
Rafailidis, P. I., Kakisi, O. K., Vardakas, K. Z., & Falagas, M. E. (2007) · Cancer · doi:10.1002/cncr.22666 · Cited by 86
Two Cases of Refractory Wegeners Granulomatosis Successfully Treated with Rituximab
Tamura, N., Matsudaira, R., Hirashima, M., Ikeda, M., Tajima, M., Nawata, M., Morimoto, S., Kaneda, K., Kobayashi, S., Hashimoto, H., et al. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6156 · Cited by 74
Cited by
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909169 · Cited by 1,748
Self-citationRituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
Greco, A., Rizzo, M. I., De Virgilio, A., Gallo, A., Fusconi, M., Ruoppolo, G., Altissimi, G., & De Vincentiis, M. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.004 · Cited by 293
Cartin‐Ceba, R., Golbin, J. M., Keogh, K. A., Peikert, T., Sánchez‐Menéndez, M., Ytterberg, S. R., Fervenza, F. C., & Specks, U. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34584 · Cited by 291
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art
Vaglio, A., Buzio, C., & Zwerina, J. (2013) · Allergy · doi:10.1111/all.12088 · Cited by 284
Metadata
- Authors
- Jones, R. B., Ferraro, A. J., Chaudhry, A. N., Brogan, P., Salama, A. D., Smith, K. G. C., Savage, C. O. S., & Jayne, D. R. W.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-06-29
- Volume
- 60
- Issue
- 7
- Pages
- 2156-2168
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1992270926
- Cited by
- 350
- References
- 33
- FWCI
- 32.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.